Northwestern University Human Resources

Calidi Biotherapeutics reported Q3 2024 net loss of $5.1 million ($0.65 per share) and key developments, including FDA clearance for NeuroNova (CLD-101) IND application and $2 million capital raise.

Industry experts discuss diversity in clinical trials, financial toxicity in cancer treatment, U.S. agency warns of China-linked phone hack, free heart & kidney health screenings in Houston, and the growth of the global radiopharmaceutical market.

People with type 2 diabetes and chronic kidney disease develop heart problems 28 years earlier for men and 26 years earlier for women compared to those without these conditions, according to a study presented at the American Heart Association meeting.

Imugene has dosed the first patient with its onCARlytics intratumoural combination trial for colorectal cancer at Northwestern University. The Phase-1 OASIS trial combines CD19 oncolytic virotherapy with blinatumomab to assess safety and tolerability. This approach aims to render 'invisible' solid cancers visible and vulnerable to CD19 therapies, potentially extending treatment options for advanced solid tumours.

Bruce Albala, a key figure in Alzheimer's disease drug development, passed away during his 40th wedding anniversary in Greece. Known for his work on β-secretase inhibitors, Albala led Eisai's BACE program, guiding elenbecestat through Phase 3 trials. Despite elenbecestat's limited success, Albala's pragmatic approach and advocacy for safer BACE inhibitor doses were highly regarded. He transitioned to academia in 2019, focusing on improving AD clinical trial efficiency.

NU-9, developed by Northwestern University, shows promise in reversing ALS and may treat other neurodegenerative diseases like Alzheimer’s and frontotemporal degeneration by addressing shared underlying mechanisms. Funded by the National Institute on Aging, NU-9 aims to improve neuron health by targeting protein aggregation, with ongoing FDA trials for safety and efficacy.

Thryv Therapeutics sponsors 2024 SADS Foundation Family Conference in Chicago, uniting experts, patients, and families to discuss Long QT Syndrome and other inherited arrhythmias.

New study in mice using peptide-brush polymers shows promise in treating Huntington's disease by preventing protein clumping and reversing symptoms, though human trials are needed.

Precision medicine, focusing on individual genes for targeted therapy, is the next big thing in healthcare, according to a Northwestern University report.

Dr. Nir Barzilai predicts impactful gerotherapeutics will take decades to reach the average person. Successful gerotherapy must target aging hallmarks, extend health span, undergo extensive clinical trials, and influence all-cause mortality. Four FDA-approved drugs show promise: GLP-1s, SGLT2 inhibitors, bisphosphonates, and metformin. Despite their potential, these drugs are not approved for anti-aging alone and are intended for those with pre-existing conditions. Lifestyle changes remain crucial for healthy aging.